psychosis is presented and compared with matched healthy controls. Three time points (baseline, 2 months, 12 months) are available for patients and two (baseline, 12 month) for controls. The possible contribution of different antipsychotics will be explored, and whether patients who were no longer using antipsychotics at the one-year follow-up have less problems in these measures. First results regarding the gut microbiome will be presented (Schwarz et al. 2017), and the possible contribution of gut microbiota to inflammation and weight gain in first-episode psychosis explored. Results: Our previous findings from a subset of the study sample found most marked changes in innate immunity chemokines (Mäntylä et al. 2015), whereas full longitudinal data on 38 cyto-and chemokines will be available at the SIRS congress. As a preliminary result on the longitudinal course of inflammation, high-sensitivity C-reactive protein showed a significant increase during the first year of treatment in patients (median baseline 0.65 mg/l, 2 months 0.79 mg/l and 12 months 1.68 mg/l). Data on PBMC gene expression will also be presented, revealing notable differences related to different antipsychotic use. Background: Psychotic patients are at high risk for developing obesity, metabolic syndrome and type 2 diabetes. These metabolic co-morbidities are hypothesized to be related to both treatment side-effects as well as to metabolic changes occurring during the psychosis. Earlier metabolomics studies have shown that blood metabolite levels are predictive of insulin resistance and type 2 diabetes in the general population as well as sensitive to the effects of antipsychotics. Here we aimed to identify the metabolite profiles predicting future weight gain and other metabolic abnormalities in psychotic patients. Methods: We applied metabolomics to investigate serum metabolite profiles in a prospective study setting in 36 first-episode psychosis patients during the first year of the antipsychotic treatment and 19 controls. Two analytical platforms with broad analytical coverage were used. Molecular lipids were analysed by ultra-high performance liquid chromatography coupled to time-of-flight mass spectrometry (UHPLC_QTOFMS) and polar metabolites were analysed by two-dimensional gas chromatography coupled to TOFMS (GCxGC-TOFMS). Ongoing prospective metabolomics studies ae focusing on the subjects in at-risk mental state. Results: While corroborating several earlier findings when comparing cases and controls and the effects of the antipsychotic medication, we also found that prospective weight gain in psychotic patients was associated with increased levels of triacylglycerols with low carbon number and double-bond count at baseline and independent of obesity, that is, lipids known to be associated with increased liver fat. Discussion: The first-episode psychotic patients who rapidly gain weight in the follow-up have early metabolic disturbances which are associated with insulin resistance and fatty liver. Our studies suggest that metabolite profiles may be used to identify the psychotic patients most vulnerable to develop metabolic co-morbidities, and may point to a pharmacological approach to counteract the antipsychotic-induced weight gain.
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THE ENDOCANNABINOID SYSTEM IN FIRST-EPISODE PSYCHOSIS
Jarmo Hietala* ,1
University of Turku
Background: The endocannabinoid (EC) system comprises of fatty acid neurotransmitters such as anandamide and 2-acylglycerol, at least two specific cannabinoid (CB) receptor subtypes and enzyme machinery for synthesis and degradation of ECs. The EC system regulates a wide array of functions in central nervous system and peripheral tissues such as brain development, plasticity, reward and stress sensitivity as well as metabolic functions a such as energy/lipid metabolism including liver function and insulin resistance (1). One of the aims of the METSY project (www.metsy.eu) is to study the central and peripheral EC system in FEPs and their involvement in brain mechanisms in psychosis as well as related metabolic co-morbidities. The cannabinoid CB1 receptor (CB1R) is the most abundant cannabinoid receptor subtype in the human brain and is the predominant mediator of various EC effects. In this first series of METSY experiments we report in vivo brain CB1R binding characteristics in patients with first-episode psychosis (FEP) and controls. Methods: Brain CB1R availability was measured using [18F]-FMPEP-d2 and 3D ECAT HRRT positron emission tomography (PET) using distribution volume (DVt) as a proxy for CB1R availability. Our studies in healthy volunteers revealed a marked sex difference in [18F]-FMPEP DVt with males having higher CB1R availability. The overall CB1R sex difference was widespread but also regionally different with most significant effects in the occipital cortex. Therefore, subsequent studies focused first on male patients with FEP and controls (n=18).
Results:
The results indicate a significant and relatively widespread decrease in CB1R DVt in patients with FEP in fronto-temporal regions, putamen, posterior cingulate as well as parietal regions with large effect sizes. Largely similar results were seen in an independent sample of medication-free male patients with FEP (n=17, the other METSY PET site, King's College, London, UK) (2). Those studies used another validated CB1R tracer, the [11C]-MePPEP. The reduced CB1R in patients was also state-dependent as [18F]-FMPEP DVt correlated negatively with psychotic symptoms (BPRS) in a highly significant manner. Discussion: Epidemiological studies have convincingly shown that cannabis use is associated with an increased risk of both psychotic symptoms and schizophrenia-like psychoses. We now provide direct in vivo evidence for a robust and partly state-dependent dysregulation of the endocannabinoid system in first-episode psychosis. This is well in line with a recent PET study with CB1R tracer, [11C]-OMAR in patients with schizophrenia (3). Based on previous experimental data the reduced CB1R availability is indicative of an increased endocannabinoid drive in psychosis. Acknowledgements: Funding from the EU's 7th Framework Programme; METSY -Neuroimaging platform for characterization of metabolic comorbidities in psychotic disorders (no. 602478). 
